Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1988 1
1989 2
1991 2
1992 4
1993 7
1994 11
1995 8
1996 4
1997 6
1998 7
1999 12
2000 13
2001 22
2002 23
2003 22
2004 22
2005 47
2006 54
2007 55
2008 49
2009 73
2010 67
2011 89
2012 83
2013 145
2014 152
2015 190
2016 162
2017 177
2018 217
2019 229
2020 314
2021 345
2022 268
Text availability
Article attribute
Article type
Publication date

Search Results

2,607 results
Results by year
Filters applied: . Clear all
Page 1
Exosomes and breast cancer drug resistance.
Dong X, Bai X, Ni J, Zhang H, Duan W, Graham P, Li Y. Dong X, et al. Among authors: duan w. Cell Death Dis. 2020 Nov 17;11(11):987. doi: 10.1038/s41419-020-03189-z. Cell Death Dis. 2020. PMID: 33203834 Free PMC article. Review.
Phospholipase iPLA2β averts ferroptosis by eliminating a redox lipid death signal.
Sun WY, Tyurin VA, Mikulska-Ruminska K, Shrivastava IH, Anthonymuthu TS, Zhai YJ, Pan MH, Gong HB, Lu DH, Sun J, Duan WJ, Korolev S, Abramov AY, Angelova PR, Miller I, Beharier O, Mao GW, Dar HH, Kapralov AA, Amoscato AA, Hastings TG, Greenamyre TJ, Chu CT, Sadovsky Y, Bahar I, Bayır H, Tyurina YY, He RR, Kagan VE. Sun WY, et al. Among authors: duan wj. Nat Chem Biol. 2021 Apr;17(4):465-476. doi: 10.1038/s41589-020-00734-x. Epub 2021 Feb 4. Nat Chem Biol. 2021. PMID: 33542532 Free PMC article.
An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer.
Li N, Bu H, Liu J, Zhu J, Zhou Q, Wang L, Yin R, Wu X, Yao S, Gu K, Zhang H, Li G, Pan H, Wu Q, An R, Yang X, Zhu Y, Wan X, Duan W, Xiong J, Guo H, Lou G, Wang J, Hu W, Zhang X, Meng Y, Zhang B, Wang Y, Wang Q, Wu L. Li N, et al. Among authors: duan w. Clin Cancer Res. 2021 May 1;27(9):2452-2458. doi: 10.1158/1078-0432.CCR-20-3546. Epub 2021 Feb 8. Clin Cancer Res. 2021. PMID: 33558426 Clinical Trial.
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
Ferrante M, Feagan BG, Panés J, Baert F, Louis E, Dewit O, Kaser A, Duan WR, Pang Y, Lee WJ, Gustafson D, Liao X, Wallace K, Kalabic J, D'Haens GR. Ferrante M, et al. Among authors: duan wr. J Crohns Colitis. 2021 Dec 18;15(12):2001-2010. doi: 10.1093/ecco-jcc/jjab093. J Crohns Colitis. 2021. PMID: 34077509 Free PMC article. Clinical Trial.
GRP78 in lung cancer.
Xia S, Duan W, Liu W, Zhang X, Wang Q. Xia S, et al. Among authors: duan w. J Transl Med. 2021 Mar 21;19(1):118. doi: 10.1186/s12967-021-02786-6. J Transl Med. 2021. PMID: 33743739 Free PMC article. Review.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. D'Haens G, et al. Among authors: duan wr. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. Lancet. 2022. PMID: 35644154 Clinical Trial.
2,607 results